One treatment with the anti-TRBC1-SG3249 ADC combination saw cancer elimination within seven days in mouse models. Researchers at the Johns Hopkins Kimmel Cancer Center and its Lidwig Center and Lustgarten Laboratory have developed a novel treatment for leukaemias and lymphomas that arise from immune system T cells. This treatment was effective at killing these cancers in mice bearing human T-cell tumours. https://www.drugtargetreview.com/news/147367/combatting-t-cell-tumours-with-antibody-drug-conjugates/